首页> 外文OA文献 >PCN137 ECONOMIC BURDEN ASSOCIATED WITH ADVERSE EVENTS AMONG PATIENTS WITH NON-METASTATIC PROSTATE CANCER TREATED WITH BICALUTAMIDE, ENZALUTAMIDE OR ABIRATERONE FOLLOWING ANDROGEN DEPRIVATION THERAPY (SURGICAL/MEDICAL CASTRATION)

【2h】

PCN137 ECONOMIC BURDEN ASSOCIATED WITH ADVERSE EVENTS AMONG PATIENTS WITH NON-METASTATIC PROSTATE CANCER TREATED WITH BICALUTAMIDE, ENZALUTAMIDE OR ABIRATERONE FOLLOWING ANDROGEN DEPRIVATION THERAPY (SURGICAL/MEDICAL CASTRATION)

机译：PCN137与雄蛋白化癌，苯甲醛或Abiraatorons治疗的非转移前列腺癌患者的不良事件相关的经济负担，如雄激素剥夺治疗（手术/医学阉割）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
A. Shah; A. Hussain; R. Shah; S. Ikeme; A. Mohamed; R. Waldeck; M. Botteman;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. NUMBER NEEDED TO TREAT AND COST PER CLINICALLY MEANINGFUL OUTCOME OF ENZALUTAMIDE AND ABIRATERONE ACETATE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT FAILED ANDROGEN DEPRIVATION THERAPY IN BRAZIL [J] . Sasse A. P., Lopes G., Teich V, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：根据临床意义评估恩扎鲁米特和醋酸阿比特雷酮用于治疗转移性抗前列腺癌的前列腺癌的治疗和费用的数字
2. Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149–56. AR-V7 Testing: What's in it for the Patient? [J] . Jun Luo, Brandon Luber, Hao Wang, European urology . 2017,第6期

机译：回复Julie Steinestel，Christof Bernemann，Andres J. Schrader，Jochen K. Lennerz的信Re：Emmanuel S. Antonarakis，ChangXue Lu，Brandon Luber等。雄激素受体剪接变异-7 mRNA检测在用第一和二线依甲酰丁酰胺处理的转移性阉割前列腺癌循环肿瘤细胞中的胃泌素受体剪接变异-7mRNA检测。 J Clin incol 2017; 35：2149-56。 AR-V7测试：患者中有什么？
3. Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9? Lead to Promotion versus Suppression of Prostate Cancer Metastasis [J] . Tzu-Hua Lin, Soo Ok Lee, Yuanjie Niu, The Journal of biological chemistry . 2013,第27期

机译：鉴别雄激素剥夺疗法与抗雄激素Casodex / Bicaletamide或MDV3100 /苯甲丁胺与抗雄激素受体ASC-J9？导致促进与前列腺癌转移的抑制
4. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer [C] . World Congress on Heart Failure--Mechanisms and Management . 2002

机译：骨质疏松症和其他不良身体成分在前列腺癌中抗剥伤治疗期间发生变化
5. Cost and Management of Fractures in Medicare Beneficiaries with Non-Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy. [D] . Yong, Candice Yuk Chen. 2015

机译：用雄激素剥夺疗法治疗的非转移性前列腺癌医疗保险受益人骨折的成本和管理。
6. Clinical outcomes of First-line Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [O] . Edoardo Francini, Steven Yip, Shubidito Ahmed, -1

机译：一线醋酸阿比特龙（AA）或恩扎鲁胺（E）用于雄激素剥夺疗法（ADT）+多西他赛（D）或仅ADT用于转移性激素敏感性前列腺癌（mHSPC）的转移性去势抵抗性前列腺癌（mCRPC）的临床结果
7. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy [O] . Anuj Shah, Ruchit Shah, Nehemiah Kebede, 2020

机译：在雄激素剥夺治疗之后，用次生激素疗法治疗的非转移前列腺癌患者的现实世界发病率和不良事件的负担

PCN137 ECONOMIC BURDEN ASSOCIATED WITH ADVERSE EVENTS AMONG PATIENTS WITH NON-METASTATIC PROSTATE CANCER TREATED WITH BICALUTAMIDE, ENZALUTAMIDE OR ABIRATERONE FOLLOWING ANDROGEN DEPRIVATION THERAPY (SURGICAL/MEDICAL CASTRATION)

著录项

相似文献

相关主题

期刊订阅